HK Stock Market Move | BRAINAURORA-B(06681) soared more than 10% in intraday trading, nearly 50% higher than its IPO price. Its core product is a brain function information management platform software system.

BRAINAURORA-B(06681) rose more than 10% in intraday trading, reaching a high of 4.78 Hong Kong dollars, an increase of nearly 50% compared to the IPO price of 3.22 Hong Kong dollars. As of the time of writing, it is up 3.23% at 4.48 Hong Kong dollars, with a trading volume of 25.53 million Hong Kong dollars. According to the prospectus, BRAINAURORA-B is a veteran participant in the Chinese cognitive impairment digital therapy market and the first company in China to combine neuroscience with artificial intelligence technology to develop medical-grade digital therapy products. BRAINAURORA-B's product pipeline covers assessment and intervention for a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children. As of October 22, 2024, BRAINAURORA-B's core product, the "Brain Function Information Management Platform Software System," is China's first regulatory-approved cognitive impairment digital therapy product. It has been commercialized for eight indications of four major types of cognitive impairment and is currently developing several other indications. The product is included in the medical insurance reimbursement catalog of 30 provinces in China. The prospectus also mentioned that the National Health Commission has partnered with BRAINAURORA-B to help establish cognitive centers in over 2100 public hospitals within the next 5 years, which will strongly promote the development of the Chinese cognitive impairment digital therapy market in the next five years.